Cardiol Therapeutics Inc. CRDL
0.95 USD -0.02 (-2.23%)
Regular-session close
0.98 +0.03 +3.16%
After hours · Nov 18, 6:39 PM ET
0.9325 Day range 0.994
0.88 52-week range 2.34
- YTD
- -0.41%
- 1 year
- -7.76%
News
prnewswire.com Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC TORONTO, Nov. 3, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
prnewswire.com Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance. The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture…
prnewswire.com Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028. TORONTO, Sept.
zacks.com 5 Small Drug Stocks Poised to Benefit From a Biotech Recovery INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
prnewswire.com Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
prnewswire.com Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference TORONTO, Sept. 9, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
zacks.com Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year? Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
zacks.com Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy? Does Cardiol Therapeutics Inc. (CRDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
marketbeat.com Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial Cardiol Therapeutics NASDAQ: CRDL is advancing its synthetic, pharmaceutical-grade cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management…
defenseworld.net Cardiol Therapeutics (CRDL) Expected to Post Earnings on Thursday Cardiol Therapeutics (NASDAQ: CRDL - Get Free Report) is expected to post its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of…
prnewswire.com Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference TORONTO, Aug. 5, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
prnewswire.com Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association • Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion. TORONTO, July 14, 2026 /PRNewswire/ -- Cardiol Therapeutics…
prnewswire.com Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit TORONTO, July 9, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
prnewswire.com Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
prnewswire.com Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT TORONTO, June 23, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
prnewswire.com Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ TORONTO, May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and…
prnewswire.com Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75%…
prnewswire.com Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU…
defenseworld.net Contrasting Corcept Therapeutics (NASDAQ:CORT) & Cardiol Therapeutics (NASDAQ:CRDL) Corcept Therapeutics (NASDAQ: CORT - Get Free Report) and Cardiol Therapeutics (NASDAQ: CRDL - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two…
newsfilecorp.com Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the…
